Showing results (121-130 of 215) with videos related to

Sort By:
Pageof 22
European Journal of Haematology|May 26, 2017
Deregulated expression of long non-coding RNA UCA1 in multiple myelomaLenka Sedlarikova, Barbora Gromesova, Veronika Kubaczkova, et al.
Annals of Hematology|April 23, 2023
Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients - real world evidence analysisMartin Stork, Ivan Spicka, Jakub Radocha, et al.
European Journal of Haematology|April 5, 2017
Genomewide association study on monoclonal gammopathy of unknown significance (MGUS)Hauke Thomsen, Chiara Campo, Niels Weinhold, et al.
Cancer|May 19, 2016
Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myelomaRobert Z Orlowski, Arnon Nagler, Pieter Sonneveld, et al.
Leukemia & Lymphoma|November 15, 2011
MyelomA Genetics International ConsortiumGareth Morgan, Hans Erik Johnsen, Hartmut Goldschmidt, et al.
Blood Cancer Journal|February 19, 2021
Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of lifeEvangelos Terpos, Joseph Mikhael, Roman Hajek, et al.
Cancers|October 27, 2022
Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent TherapyJiri Minarik, Jakub Radocha, Alexandra Jungova, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 17, 2009
Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapyPavel Nemec, Zuzana Zemanova, Henrieta Greslikova, et al.
Leukemia|July 25, 2018
European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasiasMaria Gavriatopoulou, Pellegrino Musto, Jo Caers, et al.
The Lancet. Oncology|August 28, 2017
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trialMeletios A Dimopoulos, Hartmut Goldschmidt, Ruben Niesvizky, et al.
Pageof 22